Other
CN
EU
USA
Description: Alfuzosin HCl (Alfetim; alfusozine; SL-77499; alphuzosine; Benestan; Urion; UroXatral; Xatral), the hydrochloride salt of alfuzosin, is an approved/marketed drug which acts as an alpha1 adrenergic receptor antagonist. It has been approved for use in the treatment of benign prostatic hyperplasia (BPH).
References: J Pharmacol Exp Ther. 2008 Feb;324(2):427-33; Eur Urol. 2004 Jan;45(1):110-6.
Related CAS #: 81403-68-1 (HCl) 81403-80-7(Alfuzosin).
Product Catalog 2022
Guide to Product Handling
Chemical Name: N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, monohydrochloride
InChi Key: YTNKWDJILNVLGX-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
SMILES Code: O=C(C1OCCC1)NCCCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)C.[H]Cl
SL-77499; Alfetim; alfusozine; alfuzosin; SL 77499; SL77499; alfuzosin hydrochloride; alphuzosine; Benestan; Urion; UroXatral; Xatral
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
In vitro activity: Alfuzosin significantly increases whole-cell peak sodium (hNa(v)1.5) current, increases the probability of late hNa(v)1.5 single-channel openings, and significantly shortens the slow time constant for recovery from inactivation. Alfuzosin also increases hNa(v)1.5 burst duration and number of openings per burst between 2- and 3-fold. Alfuzosin shows a concentration-dependent relaxing effect on rabbit corpus cavernosum (CC) pre-contracted by 10 mM phenylephrine.
J Pharmacol Exp Ther. 2008 Feb;324(2):427-33; Eur Urol. 2004 Jan;45(1):110-6
Purity ≥98%
COA
MSDS